A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues og glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide

Diabetes, Obesity and Metabolism

Volumn 7, Issue 5, 2005, Pages 595-604

  Green, Brian D ^a   Gault, V A ^a   O'Harte, F P M ^a   Flatt, P R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

(ob ob) mice; Diabetes; DPP IV; GIP; GLP 1; Glycation; Insulin secretion

Indexed keywords

ANTIDIABETIC AGENT; CYCLIC AMP; DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; HISTIDINE; INSULIN; SORBITOL; TYROSINE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL LINE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG STRUCTURE; ENZYME DEGRADATION; ENZYME SYNTHESIS; GLYCATION; IN VITRO STUDY; IN VIVO STUDY; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PROTEIN FUNCTION; RAT; STRUCTURE ANALYSIS;

EID: 23844434969     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2004.00455.x     Document Type: Article

References (39)

1. Meier JJ, Gallwitz B, Nauck MA. Glucagon-like peptide-1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus. Biodrugs 2003; 2: 93-102.
2. Buteau J, Roduit R, Susini S, Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999; 42: 856-864.
3. Zhou J, Wang X, Pineyro MA, Egan JM. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 1999; 48: 2358-2366.
4. Trumper A, Trumper K, Trusheim H, Arnold R, Göke B, Horsch D. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol 2001; 15: 1559-1570.
5. Pospisilik JA, Stafford SG, Demuth HU et al. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 2002; 51: 943-950.
6. Villanueva-Penacarrillo ML, Alcantara AI, Clemente F, Delgado E, Valverde I. Potent glycogenic effect of GLP-1 (7-36)amide in rat skeletal muscle. Diabetologia 1994; 37: 1163-1166.
7. O'Harte FPM, Gray AM, Flatt PR. Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle. J Endocrinol 1998; 156: 237-243.
8. Gault VA, Flatt PR, O'Harte FPM. Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem Biophys Res Common 2003; 308: 207-213.
9. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24.
10. Knudsen LB, Pridal L. Glucagon-like peptide-1-(9-36)amide is a major metabolite of glucagon-like peptide-1-(7-36)amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996; 318: 429-435.
11. Wettergren A, Wojdemann M, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (7-36)amide on antral motility is antagonised by its N-terminally truncated primary metabolite GLP-1 (9-36)amide. Peptides 1998; 19: 877-882.
12. Gault VA, Parker JC, Harriott P, Flatt PR, O'Harte FPM. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. J Endocrinol 2002; 175: 525-533.
13. Holst JJ. Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors. Adv Exp Med Biol 2003; 524: 263-279.
14. O'Harte FPM, Mooney MH, Lawlor A, Flatt PR. N-terminally modified glucagon-like peptide-1(7-36)amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo. Biochim Biophys Acta 2000; 1474: 13-22.
15. O'Harte FPM, Mooney MH, Kelly CM, McKillop AM, Flatt PR. Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice. Regul Pept 2001; 96: 95-104.
16. O'Harte FPM, Abdel-Wahab YHA, Conlon JM, Flatt PR. Amino-terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells. Biochim Biophys Acta 1998; 1425: 319-327.
17. O'Harte FPM, Mooney MH, Flatt PR. N-terminally modified gastric inhibitory polypeptide exhibits aminopeptidase resistance and enhanced antihyperglycemic activity. Diabetes 1999; 48: 758-765.
18. O'Harte FPM, Mooney MH, Kelly CMN, Flatt PR. improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide. J Endocrinol 2000; 165: 639-648.
19. O'Harte FPM, Gault VA, Parker JC et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of glucose-dependent insulinotropic polypeptide: N-Acetyl-GIP pGlu-GIP. Diabetologia 2002; 45: 1281-1291.
20. 1-modified enzyme resistant forms of GIP, is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes. Biochem J 2002; 367: 913-920.
21. 2-substituted analogues of glucose-dependent insulinotropic polypeptide. J Endocrinol 2003; 176: 133-141.
22. 2-substituted analogs of GIP with preserved biological activity in vivo. Metabolism 2003; 52: 679-687.
23. Green BD, Gault VA, Mooney MH et al. Novel DPP IV resistant analogues of GLP-1 with potent insulinotropic activity in vitro conferring improved glucose-lowering action in vivo. J Mol Endocrinol 2003; 31: 529-540.
24. 9)-substituted analogues of glucagon-like peptide-1. Biol Chem 2003; 384: 1543-1551.
25. 7-modification of GLP-1 generates DPP IV-stable analogues with potent antihyperglycaemic activity. J Endocrinol 2004; 180: 379-388.
26. Xiao Q, Giguere J, Parisien M et al. Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry 2001; 40: 2860-2869.
27. Miguel JC, Abdel-Wahab YH, Green BD, Mathias PC, Flatt PR. Cooperative enhancement of insulinotropic action GLP-1 by acetylcholine uncovers paradoxical inhibitory effect of beta cell muscarinic receptor activation on adenylate cyclase activity. Biochem Pharmacol 2003; 65: 283-392.
28. Meier JJ, Goetz O, Anstipp J et al. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. Am J Physiol Endocrinol Metab 2003; 286: E621-E625.
29. Meier JJ, Nauck MA, Siepmann N et al. Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. Metabolism 2003; 52: 1579-1585.
30. 9 substitution in glucagon-like peptide-1(7-36)amide (GLP-1) confers DPP IV resistance with cellular and metabolic actions similar to those of established antagonists GLP-1(9-36)amide and exondin (9-39). Metabolism 2004; 53: 252-259.
31. 8-substituted GLP-1 analogues. Biol Chem 2004; 385: 169-177.
32. Gallwitz B, Ropeter T, Morys-Wortmann C, Mentlein R, Siegel EG, Schmidt WE. GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro. Regul Pept 2000; 86: 103-111.
33. Liu H-K, Green BD, Gault VA, McClenaghan NH, McCluskey JT, Flatt PR. N-acetyl-GLP-1: a DPP IV resistant analogue of glucagon-like peptide-1 (GLP-1) with improved effects on pancreatic beta-cell associated gene expression. Cell Biol Int 2004; 28: 69-73.
34. Gremlich S, Porret A, Hani EH et al. Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Diabetes 1995; 44: 1202-1208.
35. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 1992; 89: 8641-8645.
36. Hareter A, Hoffmann E, Bode HP, Göke B, Göke R. The positive charge of the imidazole side chain of histidine7 is crucial for GLP-1 action. Endocrine J 1997; 44: 701-705.
37. Hinke SA, Gelling R, Manhart S et al. Structure-activity relationships of glucose-dependent insulinotropic polypeptide (GIP). Biol Chem 2003; 384: 403-407.
38. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195-202.
39. Elbrond B, Jakobsen G, Larsen S et al. Pharmacokinetics pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002; 25: 1398-1404.